– UK, Oxford – Ochre Bio, an innovator in chronic liver disease medicine development, today announced the appointment of Dr. Chinwe Ukomadu (MD, Ph.D.) to its Board of Directors as an Observer
About Dr. Chinweike Ukomadu
Dr. Chinwe Ukomadu joins Ochre Bio’s board as an observer and will act as a liaison between the company’s Scientific Strategy Board and Board of Directors. Given Dr. Ukomadu’s prior experience on Ochre Bio’s SSB and his current role as SVP and Head of GI Therapeutic Area at Takeda, he is uniquely positioned to guide the leadership team as it pertains to translating early discoveries into a pipeline of therapeutic candidates to improve patients’ lives.
Dr. Chinwe said: “It’s an honor to join a cohort of experienced members on the Ochre Bio board, each fully committed to overseeing and supporting the organization’s breakthrough work. I look forward to working with both the SSB and the Board to guide Ochre Bio on its path toward impacting patient lives. The future of chronic liver disease treatment is being shaped by Ochre Bio, built by some of the best scientific talents on a foundation of transdisciplinary excellence.”
Dr. Chinwe Ukomadu is a physician-scientist whose career spans academia, clinical care, and industry. Chinwe earned his Ph.D. (Physiology) and MD from Yale University and was an internal medicine resident and chief medical resident at Brigham and Women’s Hospital (BWH). He completed sub-specialty training in gastroenterology and a post-doctoral fellowship at BWH before joining the staff of the hospital and Harvard Medical School with roles as an independent investigator, clinician, and educator. After 21 years at BWH, Chinwe was recruited to Novartis Institutes For Biomedical Research and led the pre-clinical and translational strategy in gastroenterology and liver diseases at NIBR as well as providing translational medicine expertise for the entire liver pipeline across Novartis. In 2021, Chinwe joined Takeda Pharmaceuticals, a multinational company as its Head of the GI Therapeutic Area Unit. He is responsible for the gastroenterology pipeline and strategy in research and development and is a member of the Takeda Research and Development leadership team. Dr. Ukomadu serves on the board of several biotech companies.
About Ochre Bio
Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications.
For more information: https://www.ochre-bio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.